Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04728633 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv10
  2. Primary completion date: Jun 30, 2025 to Jan 31, 2027
    • Study completion date: Mar 31, 2026 to Jun 30, 2027
    • Secondary endpoints: 3 to 2
    • Study description expanded, about 27 words
    v9
  3. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v8
  4. Re-verified, no change to tracked fieldsv7
  5. Primary completion date: Dec 31, 2023 to Jun 30, 2025
    • Study completion date: Sep 30, 2024 to Mar 31, 2026
    v6
Show 4 earlier versionsHide 4 earlier versions
  1. Re-verified, no change to tracked fieldsv5
  2. Primary completion date: Aug 31, 2022 to Dec 31, 2023v4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jun 30, 2021 to Sep 27, 2021
    • Site details revised
    v3
  4. Start date: Mar 30, 2021 to Jun 30, 2021v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II trial studies the effect of transarterial chemoembolization in treating patients with uveal melanoma that has spread to the liver (liver metastases). Transarterial chemoembolization involves the injection of a blocking agent (gelatin sponge, ethiodized oil) and a chemotherapy agent (carmustine) directly into the artery in the liver to treat liver cancers. Chemotherapy drugs, such as carmustine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. transarterial chemoembolization with carmustine in combination with ethiodized oil and gelatin sponge may help cause the tumors in the liver to shrink or disappear.
Trial Details
NCT Number NCT04728633
Lead Sponsor Thomas Jefferson University
Conditions
(from sponsor)		 Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma, Stage IV Choroidal and Ciliary Body Melanoma AJCC V8
Related terms Uveal Melanoma
Enrollment 28 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov